MTH is an effective neuroprotective therapy in patients after cardiac arrest. Therapeutic hypothermia is recommended as a standard resuscitation care in such patients with VF/VT as initial rhythm. MTH is easy to perform and without severe side-effects or complications associated with mortality. The goal of the first part of review concentrating on MTH is to describe the mechanism of action, tools for cooling, and adverse events related to this therapeutic technique after the cardiac arrest.
Introduction
The incidence of cardiac arrest in Europe is estimated between 0.4-1 per 100 inhabitants per year, which counts between 350 000-700 000 people affected [1] . After the publication of two landmark studies [2, 3] in 2002, mild therapeutic hypothermia (MTH) began to be used increasingly be used in post-resuscitation care. In the same year, the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation stated in their recommendations that unconscious adult patients with spontaneous circulation after an out-of hospital cardiac arrest (OHCA) should be cooled to 32-34 1C for 12 h to 24 h when the initial rhythm was ventricular fibrillation (VF) [4] . In 2005, The American Heart Association incorporated MTH into its advanced cardiac life support guidelines as the late link of the chain of survival [5] . The International Liaison Committee on Resuscitation strongly suggests MTH for comatose survivors after cardiac arrest in their last Recommendation published in 2010 [6] . Recent consensus document from five international critical care societies have made the same recommendation [7] . MTH is also recommended by Czech profession societies [8] .
The goal of the first part of review concentrating on MTH is to describe the mechanism of action, tools for cooling, and adverse events related to this therapeutic technique after the cardiac arrest Table 1 .
History of therapeutic hypothermia
The therapeutic use of hypothermia has a long history. In antiquity, Hyppocrates already saved wounded soldiers in snow and ice. In the Napoleonic time the surgeon Dominique Jean Larrey noted that officers who were kept closer to the fire survived less often than soldiers who slept away from fire.
The first study dealing with therapeutic hypothermia in patients with severe head injury was published in 1945 [9] . The use of therapeutic hypothermia after cardiac arrest in humans was described in 1950s, but with uncertain benefits [10, 11] . The use of MTH as a tool to reduce cerebral oxygen demand and to improve neurological outcomes after cardiac arrest was supported by studies in dogs [12] [13] [14] . After 1998, the interest in MTH increased and first clinical studies in humans after cardiac arrest were realized and published [15, 16] .
Mechanism of action
MTH is nowadays one of the most important methods of neuroprotection. Understanding the mechanisms of action, through which MTH provides neuroprotection, will allow a c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 3 7 -e 2 4 2 better understanding about the indications for this therapy (Fig. 1) . After the cardiac arrest, level of oxygen decreases and an ischemic cascade takes place. The permanent damage of neuronal cells occurs after 5 min to 10 min of complete blood flow cessation [17] .
During the ischemia-reperfusion time the reduction in high-energy molecules, such as adenosine triphosphate (ATP), takes place. The consequence of this decrease leads to a change in metabolism from aerobic to anaerobic. Anaerobic glycolysis increases intracellular phosphate, lactate and hydrogen ions levels, resulting in intra-and extra-cellular acidosis. The acidosis increases the inflow of calcium to the cell. The acidosis and high calcium levels also stimulate the cell apoptosis and cause cell death [18] .
The concentration of intracellular calcium increases [19] Calcium enters the cell through voltage-sensitive calcium channels and agonist-operated calcium channels [20] . There is a dysfunction of sodium/potassium ATP-dependent pump and ATP-dependent channels, such as calcium, sodium, and potassium channels. This limits the calcium output from the cell and the levels of intracellular calcium further increase. The calcium inflow leads to cell membranes depolarization and extracellular release of excitatory neurotransmitters such as glutamate, activating kainite/quisqualate and N-methyl-D-aspartate receptors persistently [21] . The activation of these receptors leads to an influx of sodium and chloride into the cell, causing intracellular hyperosmolarity. The high osmolarity is followed by an influx of water into the cell, resulting in intracellular edema and neuronal death [22] .
Ischemia with subsequent reperfusion generates large amounts of free radicals such as hydrogen peroxide, super oxide and peroxynitrite. These molecules cause cell membranes peroxydation and play an important role in brain damage after ischemia [23] . There is also an increased production of pro-inflammatory mediators such as tumor necrosis factor-a and interleukin 1 [24] .
MTH reduces cerebral metabolic rate for oxygen by 6%-10% for every 1 1C temperature reduction [25] . Hypothermia is likely to lower lactate levels and other wastes from anaerobic metabolism decreasing cellular acidosis [26] . Hypothermia significantly reduces extracellular levels of excitatory neurotransmitters, including dopamine and glutamate [27] . The release of these neurotransmitters is temperature dependent [28] . The production of free radicals is associated with oxidative damage that is minimized at lower temperatures [29] . Hypothermia also delays the induction of pro-inflammatory cytokines in human peripheral blood [30] .
4.
Initiation, duration of MTH, and cooling techniques
Initiation
MTH may be divided into three parts: induction, maintenance and re-warming. The impact of timing of initiation of MTH in patients after cardiac arrest remains unclear. Experimental data suggest that MTH should be initiated as soon as possible [31] [32] [33] . However, the initiation of MTH in pre-hospital setting did not have any impact on neurological outcome in patients [34] . Two prospective clinical trials in which hypothermia was achieved within 2 h [3] or at a median of 8 h (interquartile range 4-16 h) [2] after return of spontaneous circulation (ROSC) demonstrated better outcomes in the hypothermiatreated than the normothermia-treated subjects. Pre-hospital versus in-hospital cooling has been studied in randomized control trial performed by Bernard at al. [35] Patients with VF as initial rhythm after the ROSC (n ¼234) have been included. The studied arm received two liters of ice-cold Ringer's solution from paramedics whilst the other arm received cooling after arrival to the hospital using the same method. No significant difference was observed in favorable neurological outcome at discharge between the two study arms (47.5% in the pre-hospital cooled group and 52.6% in the hospital-cooled group, respectively). In the study from Kim et al. [36] , 63 patients were randomized to receive an infusion of 0.5 l to 2.0 l of 4 1C normal saline before hospital arrival, 62 patients were left without intravenous cooling during the pre-hospital care. In-field cooling was not associated with increased complications, such as pulmonary edema. There was no significant difference in survival between the two groups. This study was limited by short transport times and missing temperature data.
Castré n at al. studied the intra-arrest cooling. The OHCA survivors were randomized to receive either trans-nasal cooling (93 patients) or standard care (101 patients) during cardiopulmonary resuscitation. After the ROSC, trans-nasal cooling continued in the studied group, in the second group MTH was initiated after hospital admission and continued for 24 h. Time to target temperature of 34 1C was shorter in the treatment group for tympanic temperature (102 min in the trans-nasally cooled group versus 282 min in control group, respectively, p¼ 0.03) not for core temperature (155 versus 284 min, p¼ 0.13). Moreover, neurological outcomes (cerebral performance categories (CPC) scale 1 to 2 at discharge: 34% in the trans-nasally cooled group and 21% in the control group, respectively) and overall survival rates (44% versus 31%) were similar in both groups [37] .
Duration
The optimal duration of cooling must not be shorter than 12 h, and may last up to 24 h. Hypothermia was maintained for 12 h [3] or 24 h [2] in studies of OHCA patients presenting with VF. Moreover, most of the clinical trials maintained the MTH for 24 h. Longer duration of MTH has not been studied in adults, but hypothermia for up to 72 h has been used safely in newborns [38] .
Re-warming
Re-warming can be achieved with the same external or internal temperature control devices used for cooling. It usually starts after 24 h of MTH. There is no consensus about the rate of re-warming, but it should be no greater than 0.25-0.5 1C per hour [39] . After the re-warming, hyperthermia should be actively avoided. MTH may lead to an increased concentration of sedative drugs because their clearance is reduced [40] . Therefore, neurologic status should be assessed after 48-72 h after re-warming.
Cooling techniques
Invasive and non-invasive cooling methods are available for the use in OHCA patients. Intravenous infusion of ice-cold (4 1C) fluids (up to 30 ml kg À1 of saline 0.9% or Ringer's lactate solution) has been shown to adequately induce MTH and is easy to use in the pre-hospital setting [41, 42] . Could fluid infusion alone is not sufficient to maintain MTH [43] . The same effect in inducing and maintaining of MTH have ice packs placed in the groins, armpits and around the head and neck or use of wet towels and fanning. Ice packs are inexpensive and easy to use but have no temperature feedback control and may cause subject over-cooling. Other external surface cooling methods include cooling blankets or fluid pads. It depends on external energy support and is therefore less portable. On the other hand, they operate with a continuous temperature feedback control. The usual cooling rate is up to 1.2 1C per hour [44] . Cooling by peritoneal, pleural or bladder lavage is possible but not generally used. The endovascular cooling system consists of an endovascular catheter containing circulating fluid. It can achieve the cooling rate of 1.5-4.5 1C. For the insertion of the catheter a large vein is needed with its possible thrombo-embolic or infectious complications. An alternative to whole body cooling is brain hypothermia. Using cranial cap devise placed around the head and neck can be easily achieved the tympanic temperature of 34 1C in 60 min. The Pre ROSC Intranasal Cooling Effectiveness (PRINCE) trial demonstrated safety and efficacy of nasopharyngeal cooling. This device delivers perfluorocarbon aerosol via a catheter into the nasopharynx and provides preferential brain cooling [37] .
Tomte et al. [45] compared intravascular and surface cooling techniques in comatose cardiac arrest survivors in a nonrandomized study. One hundred sixty seven consecutive patients were included in the study during the five-year recruitment period. There was no significant difference in survival with good neurologic function, either to hospital discharge (38% in surface-cooled group and 45% in intravascular-cooled group, respectively) or at 6-month follow-up (39% versus 45%). Time from cardiac arrest to achieve MTH was equal for both devices (surface-cooled group median 273 min., inter-quartile range 158-330 min. and intravascularcooled group 270 min., inter-quartile range 190-360 min.).
The patient's core temperature is most commonly monitored with a probe in the esophagus, bladder, rectum, pulmonary artery or by tympanic temperature measurements [46] . During the cooling, patients are sedated generally by the use of opioids and benzodiazepines. To eliminate the natural body response to decrease in core temperatureshivering -neuromuscular blockers are used.
In our coronary care units, we use ice-cold Saline solution (30 ml per kilogram during the first 30 min) during the coronary angiography or after the admission. Subsequently, we apply refrigerated cooling packs around the head, neck, trunk and groins in the combination with wet towels and fanning (Fig. 2) . Before the induction of MTH patients are sedated using midazolam and fentanyl. To prevent shivering, paralysis is induced by intravenous administration of pancuronium as a bolus that is repeated every 4 h. The temperature is controlled by bladder catheter continuously. MTH is maintained for 24 h. Patients are re-warmed passively, with the re-warming rate of 0.5 1C per hour. Sedation is discontinued after the core body temperature of 36 1C is reached. During the next 72 h, we maintain core body temperature between normal ranges. Hyperthermia is actively treated by administration of metamizolum.
Adverse effects
The most often reported adverse effects of MTH include hypokalemia, hypomagnesemia, hypocalcaemia, arrhythmias, hypotension, seizure, hyperglycemia, coagulopathy and increased incidence of pneumonia and sepsis. Hypokalemia induced by MTH is caused by the influx of potassium into the cells and increased diuresis. Regular checks of mineralogram are necessary during MTH. On the other hand, aggressive supplementation of potassium during MTH may result in hyperkalemia during re-warming [47] . MTH reduces insulin sensitivity and insulin secretion. Both of these may lead to hyperglycemia [48] . Enzymes taking part in coagulations have lower activity with hypothermia. Bleeding must be watched for and if occurs, interruption of MTH is indicated. Some authors reported the 
higher incidence of arrhythmias during MTH [49] . Controversially, in the randomized trial published by Tiainen et al. [50] the use of MTH of 33 1C for 24 h after cardiac arrest was not associated with an increase in clinically significant arrhythmias Fig. 3 . In the prospective, observational, registry-based study performed in 22 hospitals in Europe and United States the association between adverse events recorded during critical care and mortality in out-of-hospital cardiac arrest patients (n¼ 765) treated with therapeutic hypothermia was studied. Only sustained hyperglycemia (odds ratio 2.3, 95% CI 1.6-3.6, po0.001) and seizures treated with anticonvulsants (odds ratio 4.8, 95% CI 2.9-8.1, po0.001) were associated with increased mortality in a multivariate model. An increased frequency of bleeding and sepsis occurred after invasive procedures (coronary angiography, intravascular devices for cooling, intra-aortic balloon pump), but bleeding and sepsis were not independently associated with increased mortality (odds ratio 1.0, 95% CI 0.46-2.2, p¼ 0.91, and odds ratio 0.30, 95% CI 0.12-0.79, p¼ 0.01, respectively) [51] .
Conclusion
MTH is an effective neuroprotective therapy in patients after cardiac arrest. Therapeutic hypothermia is recommended as a standard resuscitation care in patients after cardiac arrest. MTH is easy to perform and without severe side-effects or complications associated with mortality. MTH should be initiated as soon as possible. Finally, at this time, we recommend the use of MTH in all cardiac arrest survivors irrespective of initial rhythm who remain unconscious after ROCS to increase the chance of brain recovery after the ischemicreperfusion injury. The optimal duration and target temperature will be hopefully known after the results of ongoing trials.
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